February 2014 in “Plastic and Reconstructive Surgery” The document doesn't provide a clear conclusion or detailed findings about the impact of certain cells on cancer treatment.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
February 2026 in “Libri Oncologici Croatian Journal of Oncology” Imiquimod shows promise as a non-invasive treatment for certain HPV-related lesions, but more research is needed to optimize its use.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
14 citations
,
August 2011 in “Journal of the American Academy of Dermatology” Imiquimod 5% cream may not work for treating scrotal extramammary Paget disease.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
January 2026 in “SKIN The Journal of Cutaneous Medicine” Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab in treating psoriasis.
11 citations
,
October 2019 in “Journal of Cancer Immunology” Combining Proton Minibeam with FLASH Radiotherapy may improve cancer treatment by reducing side effects and increasing effectiveness.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
January 2010 in “Journal of Animal Science” Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.
13 citations
,
August 1980 in “Cancer” Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
4 citations
,
September 2020 in “Cell division” XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
July 2024 in “Reactions Weekly”
3 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.
1 citations
,
June 2025 in “Supportive Care in Cancer” Docetaxel chemotherapy causes more long-term hair loss and dissatisfaction than paclitaxel.
76 citations
,
July 2019 in “Scientific Reports” Baicalin nanocapsules greatly enhance its anticancer effects on breast cancer cells.
April 2018 in “Journal of Investigative Dermatology” The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
10 citations
,
December 2024 in “Allergy” Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.